Table 3.

Impact of glucose abnormalities on virological response after interferon alpha based treatment

Ref.	Year	Country	Patients number	Patient profile	Association	Statistical method	Impact on virological response	Genotypes	Statistics
D'souza et al[63]	2005	United Kingdom	59		HOMA-IR	Multivariate	Yes	All	OR of SVR: 0.44 [0.22, 0.88]; P = 0.02
Tarantino et al[85]	2005	Italy	80		GMI	Univariate	Yes	All	40% vs 7.5%; P = 0.0009
Romero-Gomez et al[86]	2005	Spain	159		HOMA-IR	Multivariate	Yes	All	OR of SVR 0.55 [0.33, 0.93]; P = 0.012
Jian Wu et al[87]	2006	China	98		HOMA-IR	Multivariate	Yes	All	OR of SVR: 0.17; P = 0.015
Backus et al[88]	2007	United States	5944	G1, G2, G3	DM	Multivariates	Yes	All and G1	OR = 0.76 [0.64, 0.71]; P = 0.002
Conjeevaram et al[89]	2007	United States	401	G1	HOMA-IR	Multivariates	Yes	G1	OR = 0.87 [0.77, 0.99]; P = 0.028
Elgouhari et al[82]	2008	United States	183		DM	Multivariate	Yes	All	OR of SVR 0.22 [0.07, 0.55]; P = 0.003
Poustchi et al[90]	2008	Australia	82	G2, G3 non DM	HOMA-IR	Multivariate	Yes	G2, G3	OR of SVR 0.16 [0.03, 0.77]; P = 0.02
Romero-Gomez et al[91]	2008	Spain	1059		FPG	Multivariate	Yes	All	OR of SVR 0.56 [0.34, 0.93]; P < 0.02
Moucari et al[71]	2009	France	226	G4	HOMA-IR	Multivariate	Yes	-	OR of SVR: 0.19 [0.07, 0.51]; P = 0.001
Dai et al[92]	2009	Taiwan	330	G1, G2	HOMA-IR	Multivariate	Yes	G1, G2	OR of SVR 0.872 [0.79, 097]; P = 0.01
Hung et al[115]	2010	Taiwan	1470		DM	Multivariate	Yes	All	OR of SVR 0.69 [0.5, 0.96]; P = 0.029
Khattab et al[93]	2010	Egypt	131	Non DM, G4	HOMA-IR	Multivariate	Yes	G4	OR of SVR 0.07 [0.01, 0.43]; P = 0.004
Deltenre et al[94]	2011	France	2732	G1-6	IR	Meta-analysis	Yes	All	-
Eslam et al[95]	2011		2129	G1-6	IR	Meta-analysis	Yes	All	OR of SVR 0.35 [0.24, 0.51]; P = 0.0004
Del Campo et al[96]	2012	Spain	240	Non DM	HOMA-IR	Multivariate	Yes	G1, G4	OR of SVR 0.44 [0.17, 0.97]; P = 0.04
Ziada et al[77]	2012	Egypt	140	Non DM	HOMA-IR	Multivariate	Yes	All	OR of SVR 0.41 [0.18, 0.9]; P = 0.003
Laurito et al[97]	2013	Brazil	2238	G1-6	IR	Meta-analysis	Yes	All	OR of SVR 0.41 [0.3, 0.56]; P = 0.022
Abd El-Wahab et al[98]	2014	Egypt	392	Non DM	HOMA-IR	Multivariate	Yes	All	OR of virological response: 0.19 [0.1, 0.38]; P = 0.0001
Grasso et al[99]	2009	Italy	90	Non DM, G1	HOMA-IR	Multivariate	No	G1	NS
Fattovich et al[100]	2010	Italy	412		HOMA-IR	Multivariate	No	No	NS
Khattab et al[76]	2012	Egypt	107	G4	HOMA-IR	Multivariate	No	G4	NS
Brandman et al[101]	2012	United States	23	Non DM	IGT, FGP, SSGP	Univariate	No	No	NS
Aghemo et al[102]	2012	Italy	339		HOMA-IR	Univariate	No	No	NS
Fattovich et al[100]	2012	Italy	124	Non DM	HOMA-IR	Multivariate	No	No	NS
Serfaty et al[103]	2012	France	1611	G4	HOMA-IR	Multivariate	No	G4	NS
Alfaleh et al[78]	2013	Saudi Arabia	157		DM	Multivariate	No	No	NS
Younossi et al[104]	2013	United States	5781	G1	HOMA-IR	Univariate adjusted	No	G1	NS
Jung et al[105]	2014	Soutk Korea	60		HOMA-IR	Univariate	No	No	NS

¹Treated with peginterferon/ribavirin telaprevir. HCV: Hepatitis virus infection; G1: Genotype 1; SVR: Sustained virological response; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; IR: Insulin resistance; IGT: Impaired glucose tolerance; DM: Diabetes mellitus; FPG: Fasting plasma glucose; SSGP: Steady-state plasma glucose; GMI: Glucose metabolism impairment; NS: Not significant; ND: Not determined.